Drugs Made In America Acquisition Corp（DMAA）股票分析

AI 分析 of Drugs Made In America Acquisition Corp (DMAA)

持有

Currently, DMAA is trading at $10.89, which is 97.5% of its 52-week high of $10.90. The RSI is at 59.42, indicating the asset is nearing overbought territory, which suggests caution. While the stock has shown a year-to-date change of +4.87%, the forward P/E is 0, indicating a lack of earnings growth expectations. The main risk is the current ratio of 0.02, suggesting potential liquidity issues.

估值指標

Drugs Made In America Acquisition Corp（DMAA）目前預期本益比為 0.00，5 年平均預期本益比為 0.00。

預期本益比

嚴重低估

5 年均值 P/E

0.00

目前P/E

0.00

高估

0.00

低估

0.00

預期 EV/EBITDA

嚴重低估

5 年均值 EV/EBITDA

0.00

目前EV/EBITDA

0.00

高估

0.00

低估

0.00

預期股價營收比

合理

5 年均值 P/S

0.11

目前P/S

0.00

高估

1.18

低估

-0.96

Alphio AI 對 DMAA 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%DMAA

$10.91

情境價格

基

基準

基準 · 50%DMAA

$9.82

情境價格

悲

悲觀

悲觀 · 25%DMAA

$9.57

情境價格

持有 DMAA 的大戶

G

Glazer Capital, LLC

+ 持有DMAA

+3.19%

3個月報酬率

W

Wolverine Asset Management, LLC

+ 持有DMAA

-16.12%

3個月報酬率

DMAA 常見問題 —— 由 Alphio AI 解答

Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues. It operates in the Financials sector.

Currently, DMAA is trading at $10.89, which is 97.5% of its 52-week high of $10.90. The RSI is at 59.42, indicating the asset is nearing overbought territory, which suggests caution. While the stock has shown a year-to-date change of +4.87%, the forward P/E is 0, indicating a lack of earnings growth expectations. The main risk is the current ratio of 0.02, suggesting potential liquidity issues.